Seventh Framework Programme and European Commission logos

Advancing the development of life-saving drugs for cardiovascular diseases

Karolinska Institutet

Sweden

Karolinska Institutet provides robust validation of candidate targets in a clinically relevant tissue by utilizing a large biobank of carotid atherosclerotic lesions in WP3 (Target validation – clinical tissue).

Karolinska Institutet was founded by King Karl XIII in 1810 as an “academy for the training of skilled army surgeons”. Today, Karolinska Institutet is one of the world’s leading medical universities. Its mission is to contribute to the improvement of human health through research and education. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine. The Center for Molecular Medicine (CMM) at Karolinska Institutet (KI) gathers more than 400 staff members with clinical experience from Karolinska University Hospital and with research competence from KI for research on the common diseases, such as cancer and atherosclerosis. Scientists from three different research groups with a collective expertise in vascular biology, atherosclerosis research and cardiovascular genetics are participating in CarTarDis.